Intracellular Delivery III Market Entry Barriers of Nanomedicines /

A critical review is attempted to assess the status of nanomedicine entry onto the market. The emergence of new potential therapeutic entities such as DNA and RNA fragments requires that these new "drugs" will need to be delivered in a cell-and organelle-specific manner. Although efforts h...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Prokop, Aleš (Editor ), Weissig, Volkmar (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Cham : Springer International Publishing : Imprint: Springer, 2016.
Edición:1st ed. 2016.
Colección:Fundamental Biomedical Technologies,
Temas:
Medicine-Research.
Biology-Research.
Nanotechnology.
Biomedical Research.
Acceso en línea:Texto Completo
Tabla de Contenidos:
  • 1 Overview of present problems facing commercialization of nanomedicines, Aleš Prokop and Volkmar Weissig
  • 2 Precision medicine and site-specific drug delivery, Karel Petrák
  • 3 Extracellular matrix degrading enzymes for nanocarrier-based anticancer therapy, Pablo Scodeller
  • 4 Nanocarrier-based anticancer therapies with the focus on strategies for targeting the tumor microenvironment, Francisca Leonard and Biana Godin
  • 5 New approach to minimize the MPS/RES uptake resulting a reduce toxic side effects of nanodrugs, Li Liu and Chien Ho
  • 6 Authentic vascular and stromal structure in animal disease model for nanomedicine, Hiroshi Nishihara and Mitsunobu R Kano
  • 7 Ligand-targeted nanocarriers with respect to their translation into the clinic, in particular in comparison with non-targeted nano-medicines, Roy Van der Meel, Laurens J.C. Vehmeijer, Robbert Jan Kok, Gert Storm, Ethlinn V.B. van Gaaland Gert Storm
  • 8 Anti-angiogenic therapy by targeting the tumor vasculature with liposomes, Yu Sakurai and Hideyoshi Harashima
  • 9 Accessing mitochondrial targets using nanocargos, Ru Wen, Afoma C. Umeano and Shanta Dhar
  • 10 Redox-responsive nano-delivery systems for cancer therapy, Amit Singh, Thanh-Huyen Tran and Mansoor M. Amiji
  • 11 Nano-emulsions for drug delivery and biomedical imaging, Nicolas Anton, François Hallouard, Mohammed F. Attia and Thierry F. Vandamme
  • 12 The tumor microenvironment in nanoparticle delivery and the role of Imaging to navigate roadblocks and pathways, Dmitri Artemov and Zaver M Bhujwalla
  • 13 Microscopic mass spectrometry for the precise design of drug delivery systems, Yasuhiro Matsumura and Masahiro Yasunaga
  • 14 Pharmacokinetics and pharmacodynamics of nano-drug delivery systems, David Stepensky
  • 15 Intracellular drug delivery in PBPK modelling though active and passive transport processes, Lars Kuepfer, Christoph Niederalt, Thomas Wendl, Jan-Frederil Schlender, Michael Block, Thomas Eissing, Donato Teutonic
  • 16 Exploiting nanocarriers for combination cancer therapy, Yi Wen Kong, Erik C. Dreaden, Paula T. Hammond and Michael B. Yaffe
  • 17 Commercialization of nanotechnology for medical applications, David W. Hobson
  • Index.

Ejemplares similares